{"name":"WiSP Wissenschaftlicher Service Pharma GmbH","slug":"wisp-wissenschaftlicher-service-pharma-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dexamethasone for control of symptoms","genericName":"Dexamethasone for control of symptoms","slug":"dexamethasone-for-control-of-symptoms","indication":"Symptom control in inflammatory and autoimmune conditions","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Anthracycline/dexamethasone-based induction chemotherapy","genericName":"Anthracycline/dexamethasone-based induction chemotherapy","slug":"anthracycline-dexamethasone-based-induction-chemotherapy","indication":"Acute leukemia induction therapy","status":"phase_3"}]}],"pipeline":[{"name":"Dexamethasone for control of symptoms","genericName":"Dexamethasone for control of symptoms","slug":"dexamethasone-for-control-of-symptoms","phase":"phase_3","mechanism":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.","indications":["Symptom control in inflammatory and autoimmune conditions","Symptom management in conditions requiring immunosuppression"],"catalyst":""},{"name":"Anthracycline/dexamethasone-based induction chemotherapy","genericName":"Anthracycline/dexamethasone-based induction chemotherapy","slug":"anthracycline-dexamethasone-based-induction-chemotherapy","phase":"phase_3","mechanism":"Anthracycline chemotherapy intercalates into DNA to prevent replication, while dexamethasone suppresses immune-mediated inflammation and enhances chemotherapy efficacy.","indications":["Acute leukemia induction therapy","Lymphoma induction therapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFBnV2lQSEtMN2hqRFN0WWxFd1pYN2thNzVORVBWQnlrNXAtT3Z1N01DcWdvUV9YdHBicE9OaW5GY1pRd2FWSWRoMHdwdjQ5VWttMXZEdU9jN0pObEFfWUE?oc=5","date":"2020-02-18","type":"trial","source":"nature.com","summary":"Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial - nature.com","headline":"Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CL","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}